Lat­est news on ‘dev­as­tat­ing’ Ab­b­Vie drug dis­con­tin­u­a­tion; Bio­gen's worst case sce­nario; Fi­nal­ly, some M&A; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If you do not have a paid sub­scrip­tion to End­points News yet, this is the week to get it. While the ma­jor­i­ty of our news is free to read, we have a trio of in-depth fea­tures for our pre­mi­um sub­scribers this week, each ad­dress­ing a dif­fer­ent facet of drug R&D — with more to come this year. You can learn more about in­di­vid­ual or com­pa­ny plans here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.